JPMorgan Initiates Larimar at Overweight

JPMorgan starts Larimar Therapeutics at Overweight with $9 target. Stock at $3.47. Key developments on nomlabofusp.

2026-05-27 06:35|Last updated: 2026-05-27 06:37

JPMorgan Initiates Larimar at Overweight — Photo: Prepared by Bond.az

JPMorgan initiated coverage on Larimar Therapeutics (NASDAQ:LRMR) with an Overweight rating and a $9.00 price target. The stock currently trades at $3.47, signaling significant upside.

Analyst Tessa Romero set a December 2027 price target. Larimar's lead candidate is nomlabofusp, a therapy for Friedreich's ataxia.

JPMorgan expects topline results from an open-label study in Q2 2026 and FDA feedback on BLA package readiness.

Larimar plans a rolling BLA submission for accelerated approval in June 2026. If approved, nomlabofusp could be the first frataxin replacement therapy, with U.S. launch in H1 2027.

In other news, Larimar held its 2026 Annual Meeting. Citizens, William Blair, Guggenheim, and Wedbush reaffirmed positive ratings.

More News

2026-06-01 12:02

743

Legend Biotech Buy Rating Reiterated

H.C. Wainwright reiterated its Buy rating for Legend Biotech with a $50 target. Revenue up 56% over twelve months.

ANALYST RATINGS →

2026-06-01 12:01

475

Cogent Stock Price Target Raised to $55

Cogent Biosciences PEAK trial: combination therapy shows 45.6% response rate, 16.5 months PFS, FDA accepts NDA. H.C. Wainwright raises price target to $55.

ANALYST RATINGS →

2026-06-01 12:00

842

H.C. Wainwright Reaffirms Mineralys Buy

H.C. Wainwright reiterated a Buy rating on Mineralys Therapeutics with a $56 price target after positive trial data.

ANALYST RATINGS →

2026-06-01 10:33

714

Goldman Sachs Upgrades Marriott Vacations Stock

Goldman Sachs upgrades Marriott Vacations stock to Buy, price target $100. Execution potential drives earnings upside.

ANALYST RATINGS →

2026-06-01 10:32

731

Goldman Sachs Upgrades Travel + Leisure Stock to Buy

Goldman Sachs upgraded Travel + Leisure stock to Buy with a $85 price target. Learn about the company's financials, dividends, and market outlook.

ANALYST RATINGS →

2026-06-01 10:32

238

Canaccord Initiates Rare Earths Americas with Buy

Canaccord Genuity initiates Rare Earths Americas with a buy rating and $25 target. Stock at $21.85, offering 14% upside potential.

ANALYST RATINGS →

2026-06-01 10:30

651

BofA Raises Icon Stock Target to $125 on Bookings

BofA Securities raised Icon plc price target to $125, maintains Underperform. Improved booking trends and Q4 results drive revision.

ANALYST RATINGS →

2026-06-01 10:03

748

RBC Capital: Sprouts faces Kroger risk

RBC Capital keeps Sprouts rating but sees risks from Kroger price cuts. Analysis and outlook on Bond.az.

ANALYST RATINGS →

2026-06-01 09:02

551

CLSA Rates Chagee Hold on Margins

CLSA initiated Chagee Holdings with Hold rating and $10 target. Bond.az analysis reveals stock may be undervalued. Read more.

ANALYST RATINGS →

2026-06-01 08:31

594

Barclays Downgrades Sensata Stock on Valuation

Barclays downgrades Sensata stock to Equalweight on valuation concerns, but raises price target to $53. Stock surged 92% in past year.

ANALYST RATINGS →

2026-06-01 08:05

946

UBS Initiates Veritone Coverage with Neutral

UBS initiated coverage on Veritone with a Neutral rating and $2.50 price target. The AI company is better positioned for growth after transformation.

ANALYST RATINGS →

2026-06-01 08:02

892

JMP Securities Initiates Microsoft with Outperform on AI Strategy

JMP Securities initiates Microsoft with Market Outperform rating and $550 target on AI strategy. Revenue growth expected to reach 17% in FY2026.

ANALYST RATINGS →

...